Mortality and Pre‐Hospitalization Use of Renin‐Angiotensin System Inhibitors in Patients with Hypertension and Coronavirus Disease 2019 (COVID‐19)

Chen Chen; Feng Wang; Peng Chen; Jiangang Jiang; Guanglin Cui; Ning Zhou; Francesco Moroni; Javid J. Moslehi; Enrico Ammirati; Dao Wen Wang

Journal ArticleOPEN ACCESS

Mortality and Pre‐Hospitalization Use of Renin‐Angiotensin System Inhibitors in Patients with Hypertension and Coronavirus Disease 2019 (COVID‐19)

Chen C
Wang F
Chen P
et al.

Journal of the American Heart Association (2020) 9(21)

DOI: 10.1161/jaha.120.017736

N/ACitations

5Readers

Abstract

There has been significant controversy about the effects of pre-hospitalization use of renin-angiotensin system (RAS) inhibitors on the prognosis of patients with hypertension and coronavirus disease 2019.

Cite

CITATION STYLE

APA

Chen, C., Wang, F., Chen, P., Jiang, J., Cui, G., Zhou, N., … Wang, D. W. (2020). Mortality and Pre‐Hospitalization Use of Renin‐Angiotensin System Inhibitors in Patients with Hypertension and Coronavirus Disease 2019 (COVID‐19). Journal of the American Heart Association, 9(21). https://doi.org/10.1161/jaha.120.017736

Mortality and Pre‐Hospitalization Use of Renin‐Angiotensin System Inhibitors in Patients with Hypertension and Coronavirus Disease 2019 (COVID‐19)

Abstract

Cite

Register to see more suggestions